ArticleJournal of neuro-oncology2017
Combined BRAF
Open access · greenAbstract read
In one paragraph
Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.International journal of clinical oncology · 2026Pooled it
- Current Perspectives on Pediatric Low-Grade Gliomas: Focus on BRAF and MEK Inhibition.Brain tumor research and treatment · 2026Review
- Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Clinical Outcome of Patients with Epithelioid Glioblastoma Harboring BRAFV600E Mutation; A Single Institution Experience.South Asian journal of cancer · 2025Article
- Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.Acta neuropathologica communications · 2024Article
- Synthesis and Structure Determination of Substituted Thiazole Derivatives as EGFR/BRAFPharmaceuticals (Basel, Switzerland) · 2023Article
- Review
- Successes and challenges in modeling heterogeneous BRAFFrontiers in oncology · 2023Review
- SPI1-mediated MIR222HG transcription promotes proneural-to-mesenchymal transition of glioma stem cells and immunosuppressive polarization of macrophages.Theranostics · 2023Article
- NTRK-fusions in pediatric thyroid tumors: Current state and future perspectives.Cancer genetics · 2022Review
- Resistance mechanisms in BRAFFrontiers in oncology · 2022Review
- Review: Neurological Complications From Therapies for Pediatric Brain Tumors.Frontiers in oncology · 2022Review
- Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.Cancers · 2021Review
- Liquid Biomarkers for Pediatric Brain Tumors: Biological Features, Advantages and Perspectives.Journal of personalized medicine · 2020Review
- Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors.Paediatric drugs · 2020Review
- Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas.Journal of neuro-oncology · 2019Article
- Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.Neuro-oncology · 2019Article
- Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.Acta neuropathologica communications · 2019Article
- Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Jie ZhangDepartment of Pediatrics, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Tsun-Wen YaoDepartment of Pediatrics, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Rintaro HashizumeDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Tarry Building, 300 E Superior, Chicago, IL, 60611, USA.
Sujatmi HarionoDepartment of Pediatrics, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Krister J BarkovichDepartment of Neurology, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Qi-Wen FanDepartment of Neurology, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Michael PradosDepartment of Pediatrics, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
C David JamesDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Tarry Building, 300 E Superior, Chicago, IL, 60611, USA.
William A WeissDepartment of Pediatrics, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA.
Theodore NicolaidesDepartment of Pediatrics, University of California San Francisco, 1450 3rd Street, San Francisco, CA, 94158, USA. Theodore.Nicolaides@ucsf.edu.
University of California, San Francisco · USNeurological Surgery · USNorthwestern University · US
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MThe vascular niche in glioma propagation and resistance to therapyU54CA163155 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE, WEAVER, VALERIE MARIE · 2011 to 2015
$4.4MBRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to TherapyR01NS080619 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES, CHARLES DAVID, PETRITSCH, CLAUDIA KATHARINA · 2012 to 2016
$1.8MTargeting histone demethylase activity for the treatment of pediatric brainstem gliomaR01NS093079 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HASHIZUME, RINTARO · 2015 to 2019
$1.5MGenetic network analysis of cancer targetsU01CA176287 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2013 to 2016
$1.2MOptimizing EGFR Targeted Therapy in Malignant GliomaK08NS065268 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NICOLAIDES, THEODORE · 2010 to 2014
$821kNCI NIH HHS P30 CA082103NCI NIH HHS P50 CA097257NCI NIH HHS U01 CA176287NCI NIH HHS U54 CA163155NINDS NIH HHS K08 NS065268NINDS NIH HHS R01 NS080619NINDS NIH HHS R01 NS093079
Abstract
BRAF
Indexed as
MAP Kinase Signaling SystemAnimalsAntineoplastic AgentsBenzamidesCell Cycle CheckpointsCell Line, TumorDiphenylamineDisease Models, AnimalFemaleGliomaHumansIndolesMiceMice, Inbred BALB CMutationProto-Oncogene Proteins B-rafAntineoplastic AgentsBenzamidesBRAF protein, humanDiphenylamineIndolesmirdametinibPLX 4720Proto-Oncogene Proteins B-rafSulfonamidesBRAFV600EEGFRMEKPediatric gliomaSecondary malignancy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.